5.1 Written Description Requirement
Key Takeaways
- 35 U.S.C. § 112(a) requires the specification to contain a written description of the invention that demonstrates the applicant was in possession of the claimed subject matter as of the filing date.
- In Ariad Pharmaceuticals, Inc. v. Eli Lilly & Co. (598 F.3d 1336), the Federal Circuit confirmed that the written description requirement is separate and distinct from the enablement requirement.
- To support a generic claim (genus), the specification must disclose a representative number of species or identifying characteristics common to the members of the genus.
- Unpredictable arts (chemical and biotechnology) require significantly more structural disclosure to satisfy written description than predictable arts (mechanical and electrical).
- Original claims constitute their own written description as filed, but post-filing claim amendments or new claims must find explicit or inherent support in the original disclosure under MPEP § 2163.
5.1 Written Description Requirement
Under 35 U.S.C. § 112(a) (and for pre-AIA applications, 35 U.S.C. § 112, first paragraph), a patent specification must contain a written description of the invention. The written description requirement serves a vital public function: it ensures that the inventor had actual possession of the claimed subject matter as of the filing date, preventing an applicant from later claiming subject matter that was not part of their original invention.
MPEP § 2163 core standard: The written description requirement requires the specification to describe the claimed invention in sufficient detail that one skilled in the art can reasonably conclude that the inventor had possession of the claimed invention at the time the application was filed.
The Ariad Benchmark: Separate and Distinct Requirement
For many years, patent practitioners debated whether the written description requirement was merely an element of enablement or a standalone statutory requirement. In the landmark en banc decision Ariad Pharmaceuticals, Inc. v. Eli Lilly & Co., 598 F.3d 1336 (Fed. Cir. 2010), the Federal Circuit definitively resolved this issue.
The court held that 35 U.S.C. § 112(a) contains two separate and distinct disclosure requirements:
- Written Description Requirement: Requiring the applicant to demonstrate possession of the claimed invention as of the application filing date.
- Enablement Requirement: Requiring the applicant to teach a person ordinarily skilled in the art (POSITA) how to make and use the claimed invention without undue experimentation.
An application may enable a POSITA to make and use a broad invention (for example, by describing a functional screening test or a general research technique), yet still fail the written description requirement if the specification fails to describe actual physical or chemical structures that constitute the invention itself.
The Legal Possession Standard
To satisfy the written description requirement, the specification must convey with reasonable clarity to those skilled in the art that the inventor possessed the claimed invention. Possession is not a mental state; it is demonstrated solely through the objective evidence within the four corners of the patent disclosure.
How Possession Is Proven
- Exact structural descriptions: Chemical formulas, mechanical schematics, genomic sequences, or step-by-step algorithms.
- Sufficient species disclosure: Providing representative species that establish ownership of a generic invention.
- Functional characterization: Describing functional attributes combined with clear structural correlation, operational parameters, or binding characteristics.
- Inherent disclosure: Disclosing features that inherently exist within the expressly described embodiments.
Genus vs. Species Disclosures
A central focus of Patent Bar questions involves claims directed to a genus (a broad class of compounds, structures, or methods) supported by a disclosure of specific species (individual members of that class).
Requirements for Genus Claims
To support a genus claim, the specification does not necessarily need to disclose every species within the genus. However, under MPEP § 2163.05, the applicant must disclose either:
- A representative number of species falling within the scope of the genus; or
- Structural features common to members of the genus that allow a POSITA to recognize which compounds or elements belong to the claimed class.
| Attribute | Predictable Arts (Mechanical/Electrical) | Unpredictable Arts (Chemical/Biotech) |
|---|---|---|
| Predictability Level | High — mechanical equivalents perform predictably | Low — minor chemical structure changes alter function |
| Species Required | Single or few species often support broad genus | Multiple representative species across scope required |
| Functional Claims | Frequently acceptable if structure is well known | Strictly scrutinized; pure functional language rejected |
| MPEP Reference | MPEP § 2163.05(a) | MPEP § 2163.05(b) |
In chemical and biological arts, disclosing a single species or a narrow sub-genus generally will not support a broad genus claim unless there is a clear structural pattern disclosed that defines the boundaries of the genus.
Original Claims vs. Amended Claims
Patent examiners evaluate written description differently depending on whether the claims were present in the application as originally filed or added during prosecution.
1. Original Claims
Original claims are part of the original disclosure. As established in In re Koller, 613 F.2d 819 (CCPA 1980), original claims constitute their own written description. If an original claim contains explicit structural details not mentioned in the specification narrative, the claim itself provides the required written description.
Exam Trap: If an original claim is broader than the detailed description in the specification, it is generally NOT rejected for lack of written description under § 112(a) solely because the specification narrative is narrower. However, it may be rejected for lack of enablement under § 112(a) if the specification does not enable the full scope of that broad original claim.
2. Amended Claims & Post-Filing Amendments
When an applicant amends a claim or adds a new claim during prosecution (e.g., in response to prior art rejections under § 102 or § 103), the examiner must check for written description support under MPEP § 2163.06:
- Broadening Amendments: Amending a claim to remove a limiting feature requires that the original specification reasonably conveyed that the feature was optional or not essential to the invention.
- Sub-genus Amendments: Amending a claim to recite a specific sub-genus or species not explicitly mentioned in the original application requires evidence that POSITA would recognize the sub-genus as specifically envisioned by the inventor.
- Claims versus disclosure amendments: A new or amended claim lacking original support is rejected under 35 U.S.C. § 112(a). New matter added to the specification, abstract, or drawings is instead objected to under 35 U.S.C. § 132 and must be canceled.
Predictability of the Technical Field
The degree of detail required to satisfy the written description requirement varies directly with the predictability of the art:
- Predictable Arts (e.g., mechanical fasteners, basic electronics): A POSITA can readily extrapolate from a single disclosed embodiment to generic variations. A claim to a 'fastener' is supported by a disclosure of a 'bolt' if fasteners were well-known mechanical equivalents.
- Unpredictable Arts (e.g., monoclonal antibodies, gene therapy, small-molecule pharmaceuticals): A POSITA cannot reliably predict structure-function relationships. A claim defining an antibody solely by its target antigen (functional language) fails the written description requirement unless the disclosure provides structural details of representative antibodies (Noelle v. Lederman, 355 F.3d 1343).
In Ariad Pharmaceuticals, Inc. v. Eli Lilly & Co., how did the en banc Federal Circuit define the relationship between the written description requirement and the enablement requirement under 35 U.S.C. § 112(a)?
Under MPEP § 2163, what is required to satisfy the written description requirement for a claim directed to a broad genus in an unpredictable art like biotechnology or chemistry?
Which statement correctly describes the written description standard applied to original claims versus claims amended during prosecution?
When an applicant amends a claim to remove a structural limitation, what must the original specification demonstrate to avoid a written description rejection under 35 U.S.C. § 112(a)?